Currently, three drug-device combinations, namely Herceptin® SC Injector (Roche), Neulasta® (pegfilgrastim) OnPro™ Kit (Amgen / Insulet) and Repatha® Pushtronex™ System (Amgen / West Pharmaceutical Services) have received USFDA approval and D-Mine® Pump (EVER Pharma / Sensile Medical) has received the CE approval. The market is poised to witness significant growth as several more large volume wearable injectors are approved for the delivery of non-insulin drugs, in the foreseen future. Our estimates suggest that the market for devices designed to deliver non-insulin drugs is expected to grow from to USD 600 million by 2030, at an annualized rate of close to 39%.
The revenues in 2025, are expected to be dominated by patch pump injectors (65%) due to their convenient usage and ergonomic handling. This trend is likely to persist in the future as well. Further, revenues from the sales of disposable injectors are likely to represent the majority market share (85%) in 2030; this is primarily due to the fact that these devices are safer to use in comparison to reusable injection devices. In terms of therapeutic indication, the significant market share (60%) is anticipated to be captured by large volume wearable injectors for the treatment of oncological and neurological disorders by 2030.
In terms of geography, presently, the major contribution to the market is made by North America (55%), followed by Europe (38%) and Asia-Pacific (7%). However, in the next decade, the market in Asia-Pacific is poised to grow at a relatively faster pace due to growing cases of chronic diseases in the developing countries of Asia-Pacific.
The market for insulin delivering large volume wearable injectors is estimated to be valued at USD 2,738 million by 2030, growing at an annualized rate of 5.5% between 2020 and 2030. The market is likely to be dominated by reusable patch pump injectors. Further, by 2030, North America and Europe are anticipated to capture 82% of the market share.
In fact, in an interview with the chief executive officer of a US-based medical device company, he stated that “The insulin delivery devices market is worth USD 3 billion. I believe that the capability of these devices to deliver different drugs will make the market even larger in the coming years. Given that these devices (large volume wearable injectors) have applications in almost every country (or therapeutic area), I believe that this is likely to be a very promising market.”
